New Data From SGO 2023
Expert Insight on New Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian Cancers

Released: May 04, 2023

Linda R. Duska
Linda R. Duska, MD, MPH
David Scott Miller
David Scott Miller, MD, FACOG, FACS

Activity

Progress
1
Course Completed

In this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including:

  • NRG GY018: randomized phase III study evaluating standard of care of carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with endometrial cancer
  • ENGOT-EN6/GOG-3031/RUBY: randomized, placebo-controlled phase III study of dostarlimab plus standard-of-care chemotherapy in primary advanced or recurrent endometrial cancer 
  • Phase I NRG-GY017 study of priming-dose atezolizumab before or concurrently with chemoradiotherapy in locally advanced high-risk cervical cancer
  • Randomized phase II study of chemoradiation plus pembrolizumab immunotherapy in locally advanced cervical cancer
  • GOG 3026: phase II trial of letrozole plus ribociclib in women with recurrent low-grade serous ovarian cancer